Cargando…

Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy

Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysp...

Descripción completa

Detalles Bibliográficos
Autor principal: Juel, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646293/
https://www.ncbi.nlm.nih.gov/pubmed/29109876
http://dx.doi.org/10.1155/2017/8905372
_version_ 1783272053345878016
author Juel, Jacob
author_facet Juel, Jacob
author_sort Juel, Jacob
collection PubMed
description Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.
format Online
Article
Text
id pubmed-5646293
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56462932017-11-06 Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy Juel, Jacob Case Rep Gastrointest Med Case Report Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy. Side effects are commonly of oropharyngeal and gastrointestinal nature, for example, swelling, itching, irritation, ulceration of the oropharynx and nausea, abdominal pain, vomiting, and diarrhoea. More serious side effects are dominated by respiratory tract and systemic manifestations. A 30-year-old male experienced refractory, relentless, and debilitation GORD subsequent to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms. Hindawi 2017 2017-10-04 /pmc/articles/PMC5646293/ /pubmed/29109876 http://dx.doi.org/10.1155/2017/8905372 Text en Copyright © 2017 Jacob Juel. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Juel, Jacob
Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title_full Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title_fullStr Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title_full_unstemmed Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title_short Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
title_sort debut of gastroesophageal reflux concomitant with administration of sublingual immunotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646293/
https://www.ncbi.nlm.nih.gov/pubmed/29109876
http://dx.doi.org/10.1155/2017/8905372
work_keys_str_mv AT jueljacob debutofgastroesophagealrefluxconcomitantwithadministrationofsublingualimmunotherapy